{"links":{"html":"https://www.erudio.com/reports/izabright-lung01-nct07100080","json":"https://www.erudio.com/reports/izabright-lung01-nct07100080.json","markdown":"https://www.erudio.com/reports/izabright-lung01-nct07100080.md","mcp":{"server":"https://mcp.erudio.com/free","tool":"get_report_card","arguments":{"slug":"izabright-lung01-07100080"}},"request":"https://www.erudio.com/contact?report=izabright-lung01-07100080"},"offer":{"cited_commentary_sources":13,"verified_hcp_statements":32,"currency":"USD","delivery":{"checkout":"online","current_edition":"Emailed as soon as payment clears: downloads, a license key and a prompt that connects your AI agent through Erudio MCP. One key per email address holds every report bought with it.","refresh":"A purchase starts a check for new commentary. A new edition, if one results, is sent to the buyer at no charge."},"identities":{"adds":"Verified IDs for the clinicians in the report, led by the NPI, so a Medical Affairs team can connect the report's voices to the expert and insight records it keeps by NPI: also X, Bluesky, LinkedIn and web pages, ORCID and OpenAlex where verified, inline on each person card (identifiers.status included). Without the add-on, each card's identifiers.status says whether the person is verified. For scientific and insight use inside the organization, including non-promotional engagement such as advisory boards and scientific exchange under its own compliance process; not for promotional targeting. Every report already names and describes its speakers and includes CMS-reported financial relationships. Sample: https://www.erudio.com/report-sample.json","available_with":"12-month updates","cap_usd":750,"identity_verified_people":9,"optional":true,"price_per_verified_person_usd":15,"price_usd":135,"product":"updates-12-identities","terms":"Priced on the identity-verified people in the edition at purchase; people verified later in the term come at no charge."},"one_off_usd":750,"purchase":{"agents":{"free_mcp":"https://mcp.erudio.com/free","keys":"One license key holds every report: get_order returns it once paid (store it as a secret), send it as licence_key with every later create_order so new reports join it. The buyer gets their account key by email, which reads every report bought with their address; recover_key (POST /api/keys/recover) with the buyer's email sends it again.","mcp_flow":["1. search_reports: Find reports by trial, NCT ID, drug, indication or sponsor. Each result has its page URL and price.","2. get_report_card: Preview one report with the slug from search_reports: what it covers, its findings and limits, and the price of each product.","3. create_order: Order the current edition or weekly updates for your person. It returns the quote, a checkout_url for your person to pay by card and, when offered, a pay_url your own payment client can pay over HTTP 402 (MPP or x402). Nothing is charged until one is paid.","4. get_order: Once the order is paid, it returns the license key. Store the key as a secret and send it as licence_key with every later create_order, so one key holds every report.","5. read_report: Read the report in full or by section on https://mcp.erudio.com/mcp, with the key as Authorization: Bearer. get_report_changes shows what a newer edition changed."],"order_endpoint":"https://www.erudio.com/api/orders","order_request":{"buyer_email":"name@company.com","idempotency_key":"optional, one per purchase","licence_key":"optional: your key from an earlier purchase","organization":"optional","product":["edition","updates-3","updates-6","updates-12","updates-12-identities"],"report":"izabright-lung01-nct07100080"},"steps":"Create the order (with licence_key if you hold one) and show checkout_url to your person to pay by card. If the order also returns pay_url, you can pay it yourself instead: POST pay_url answers 402 Payment Required with MPP or x402 offers for your payment client. Once paid, status_url (or get_order) returns the license key, the MCP setup and downloads."},"contact":{"email":"hello@erudio.com","form":"https://www.erudio.com/contact?report=izabright-lung01-07100080","people":"Audun Utengen and Tom Lee, the founders","use_for":"Questions, invoices, purchase orders"},"methods":["card (Stripe Checkout)"],"people":"https://www.erudio.com/reports/izabright-lung01-nct07100080","renewal":"Subscriptions are prepaid and do not renew automatically.","upgrades":"What the buyer already paid on this trial counts toward a longer plan: a one-off edition within 30 days, or an active plan at any time in its term. The buyer pays the difference; an upgraded plan keeps its original start, and an upgraded one-off starts the plan on payment. Order the longer product with create_order and the buyer's licence_key (or on the report page with the buyer's email); the quote shows the credit.","terms":"https://www.erudio.com/terms"},"size":"focused","size_rule":"Focused: 1–150 verified statements","updates_usd":{"3_months":1300,"6_months":1900,"12_months":2600},"volume_discounts":[{"min_subscribed_trials":10,"percent_off_updates":25},{"min_subscribed_trials":5,"percent_off_updates":15}]},"publication_state":"public","record":{"change":{"changed_finding_ids":{"reason":"No changed finding IDs recorded.","status":"none"},"last_checked_at":"2026-10-29T08:22:30.641353Z","notify_subscribers":false,"status":"new","summary":{"reason":"First accepted edition: there is no earlier edition to compare.","status":"not_applicable"}},"contents":{"aspect_coverage":{"assessment_incomplete":0,"discussed":11,"no_commentary_found":1},"aspects":[{"claim_count":3,"coverage":"discussed","id":"T1","registry_field":"outcomesModule.primaryOutcomes[0]","source_count":1,"title":"Primary endpoint: Recommended Phase 3 Dose (RP3D) of BMS-986507"},{"claim_count":5,"coverage":"discussed","id":"T2","registry_field":"outcomesModule.primaryOutcomes[1]","source_count":4,"title":"Primary endpoint: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)"},{"claim_count":9,"coverage":"discussed","id":"T3","registry_field":"outcomesModule.secondaryOutcomes","source_count":8,"title":"Secondary endpoints"},{"claim_count":7,"coverage":"discussed","id":"T4","registry_field":"conditionsModule","source_count":7,"title":"Population and setting"},{"claim_count":5,"coverage":"discussed","id":"T5","registry_field":"armsInterventionsModule.armGroups","source_count":5,"title":"The comparison"},{"claim_count":10,"coverage":"discussed","id":"T6","registry_field":"armsInterventionsModule.interventions","source_count":6,"title":"Safety and tolerability"},{"claim_count":0,"coverage":"no_commentary_found","id":"T7","registry_field":"designModule","source_count":0,"title":"Design and conduct"},{"claim_count":4,"coverage":"discussed","id":"A1","source_count":4,"title":"Sequencing, competing options and continued EGFR inhibition"},{"claim_count":1,"coverage":"discussed","id":"A2","source_count":1,"title":"Intracranial activity and brain-metastasis subgroup uncertainty"},{"claim_count":1,"coverage":"discussed","id":"A3","source_count":1,"title":"Predictive biomarkers and ADC construct-related questions"},{"claim_count":6,"coverage":"discussed","id":"A4","source_count":3,"title":"Global translatability, evidence maturity and regulatory interpretation"},{"claim_count":3,"coverage":"discussed","id":"A5","source_count":3,"title":"Research access and anticipated development timing"}],"counts":{"cited_sources":14,"claims_by_expression_type":{"comparison":1,"experience":1,"interpretation":8,"opinion":4,"primary_context":2,"question":1,"restatement":10,"uncertainty":2,"unspecified":3},"claims_by_kind":{"protocol_statement":2,"source_observation":30},"clinician_statements":12,"evidence_units":17,"findings":6,"organisational_accounts":1,"people_cited":11,"people_identity_verified":9,"people_total":11,"screened_sources":23,"verified_claims":32},"depth":"standard","findings_index":[{"id":"F1","structure":{"claims":3,"claims_by_group":{"comparisons":0,"experience":1,"questions":0,"restated":2,"views":0},"has_counterview":false,"limitations":2,"links":{"context":0,"support":3},"ma_question":true,"named_voices":2,"passages":3,"sources":3,"sources_by_kind":{"commentary":2,"registry":1}},"title":"A reported control-arm amendment makes the relevant treatment benchmark a live question"},{"id":"F2","structure":{"claims":9,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":4,"views":4},"has_counterview":false,"limitations":4,"links":{"context":1,"support":10},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Favorable China evidence encourages global development, but does not settle efficacy ranking or survival benefit"},{"id":"F3","structure":{"claims":10,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":6,"views":3},"has_counterview":true,"limitations":3,"links":{"context":3,"support":11},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Manageability judgments coexist with substantial severe toxicity and differing pulmonary-safety reports"},{"id":"F4","structure":{"claims":8,"claims_by_group":{"comparisons":1,"experience":0,"questions":1,"restated":6,"views":0},"has_counterview":false,"limitations":4,"links":{"context":2,"support":8},"ma_question":true,"named_voices":5,"passages":5,"sources":5,"sources_by_kind":{"commentary":5}},"title":"Early-phase enthusiasm depends on cohort, prior treatment and the meaning of reported dose advancement"},{"id":"F5","structure":{"claims":4,"claims_by_group":{"comparisons":0,"experience":0,"questions":1,"restated":0,"views":3},"has_counterview":false,"limitations":3,"links":{"context":1,"support":4},"ma_question":true,"named_voices":4,"passages":4,"sources":4,"sources_by_kind":{"commentary":4}},"title":"ADC substitution is not the only positioning question: sequencing and continued EGFR inhibition remain open"},{"id":"F6","structure":{"claims":2,"claims_by_group":{"comparisons":0,"experience":0,"questions":0,"restated":0,"views":2},"has_counterview":false,"limitations":2,"links":{"context":2,"support":2},"ma_question":true,"named_voices":1,"passages":1,"sources":1,"sources_by_kind":{"commentary":1}},"title":"CNS activity and predictive selection are promising areas with unresolved evidence requirements"}],"medical_affairs_question":"What benefit–toxicity evidence against the clinically relevant comparator would justify replacement rather than continued EGFR inhibition or another post-TKI option?","sections":{"analysis":[{"id":"section-1","level":2,"title":"A reported control option changes the practical benchmark"},{"id":"section-2","level":2,"title":"Positive read-through is not a settled global benefit or ranking"},{"id":"section-3","level":2,"title":"Manageability depends on the study and supportive-care conditions"},{"id":"section-4","level":2,"title":"Early-phase activity needs its cohort and development context"},{"id":"section-5","level":2,"title":"Positioning includes sequencing and the unresolved continuation question"},{"id":"section-6","level":2,"title":"CNS and biomarker questions concern selection, not established rules"},{"id":"section-7","level":2,"title":"Scope and coverage"}],"executive_summary":{"reason":"Reviewed narrative has no headings.","status":"unavailable"}},"study_design":"interventional, randomized, parallel, phase2, phase3","trial_dimensions":[{"findings":[{"id":"F3","shared_claims":3},{"id":"F4","shared_claims":2}],"id":"T1","label":"Primary endpoint: Recommended Phase 3 Dose (RP3D) of BMS-986507"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":1},{"id":"F4","shared_claims":1}],"id":"T2","label":"Primary endpoint: Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)"},{"findings":[{"id":"F2","shared_claims":4},{"id":"F3","shared_claims":4},{"id":"F4","shared_claims":4}],"id":"T3","label":"Secondary endpoints"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":2},{"id":"F4","shared_claims":4},{"id":"F5","shared_claims":3}],"id":"T4","label":"Population and setting"},{"findings":[{"id":"F1","shared_claims":1},{"id":"F2","shared_claims":2},{"id":"F3","shared_claims":1},{"id":"F5","shared_claims":1}],"id":"T5","label":"The comparison"},{"findings":[{"id":"F2","shared_claims":1},{"id":"F3","shared_claims":9},{"id":"F4","shared_claims":3}],"id":"T6","label":"Safety and tolerability"},{"findings":[],"id":"T7","label":"Design and conduct"}]},"identity":{"accepted_at":"2026-10-29T08:22:30.641353Z","edition_number":1,"previous_run_id":{"reason":"First accepted catalog edition.","status":"not_applicable"},"previous_version":{"reason":"First accepted catalog edition.","status":"not_applicable"},"product_contract":"hcp-commentary-1","published_at":"2026-10-29T08:25:50Z","record_hash":"7ee71cd02bd876b7d158e158645ce847dedb36c9f6939ecde93bfbee2c459608","release_hash":"4424a0b982367f149bf411cae8ed4c9b9652c0bddaf62a632c8d65a5bc8ffb15","report_id":"erudio-nct07100080","run_id":"108005c3-ecf2-4080-ba1c-9824a93332e0","schema_version":"5.0","slug":"izabright-lung01-07100080","version":"1.0.0","version_reason":"initial"},"offer":{"bundle_eligible":{"reason":"Owner has not set bundle_eligible.","status":"not_set"},"license_ref":{"reason":"Owner has not set license_ref.","status":"not_set"},"request_route":{"reason":"Owner has not set request_route.","status":"not_set"},"single_edition":{"reason":"Owner has not set single_edition.","status":"not_set"},"updates":{"reason":"Owner has not set updates.","status":"not_set"}},"preview":{"abstract":"IZABRIGHT-Lung01 tests izalontamab brengitecan against pemetrexed plus platinum chemotherapy in EGFR-mutated NSCLC progressing after third-generation EGFR-TKI treatment. In the sources reviewed for this edition, an X poster’s enthusiasm for global development remains conditional. External efficacy signals draw enthusiasm in an X post, while toxicity draws concern in an X post. The relevant treatment benchmark and efficacy ranking remain unresolved questions in these sources.","meta_description":"23 sources screened · 32 verified statements (12 from clinicians verified by NPI or staff page) from 14 sources · 6 findings. Updated Oct 29, 2026.","person_names_policy":"role_only","sample_findings":[{"cited_claim_ids":["claim-263e095bf0e553bf555c"],"id":"F4","paraphrase":"How should treatment history shape interpretation of early-phase iza-bren activity? This question is explored through an X post.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-09-14","title":"Early-phase enthusiasm depends on cohort, prior treatment and the meaning of reported dose advancement"},{"cited_claim_ids":["claim-68d0e8e43091611df1f7"],"id":"F1","paraphrase":"Which comparator should frame evaluation of iza-bren after EGFR-TKI progression? This question is examined through an X post.","publication_caveats":{"reason":"Publication caveats are not specified for this source.","status":"not_set"},"source_channel":"x_thread","source_date":"2026-10-26","title":"A reported control-arm amendment makes the relevant treatment benchmark a live question"}]},"publication":{"approved_at":"2026-10-29T08:25:50Z","approved_by":"Erudio publisher","corrections":[],"rights_status":"cleared: short attributed excerpts with link-out; no-derivatives sources suppressed; role-only names in previews","state":"public"},"schema_id":"erudio.catalog_record","schema_version":"2.1","scope_and_limits":{"commentary_scope":{"basis":"Only the sources used in this report; not all HCPs or all public discussion.","has_known_gaps":true,"source_count":23},"does_not":["judge efficacy","estimate HCP prevalence or consensus","give treatment advice"],"known_gaps":["Discussion that does not name the trial may be missing from this edition.","Not yet captured in this edition: a view on balancing efficacy and severe treatment-related toxicity when choosing treatment after EGFR-TKI progression.","Some passages in the sources used in this report were not fully assessed for clinician views, so a view there may be missing from this edition.","13 statements in the sources reviewed for this edition are about other patients or topics, or only mention the trial, and are not counted.","Further source limits: discussion that describes the trial without naming it may be incomplete; some discussion that describes the trial without naming it may be missing; sources about other trials are not included.","The discussion reviewed is not a representative sample of HCP opinion. Reposts show circulation, not additional independently expressed agreement.","No full protocol document or results publication for NCT07100080 was available. Favorable efficacy and safety statements concern PANKU-Lung01 or earlier development unless explicitly described otherwise.","The reported chemotherapy-plus-amivantamab control option is a speaker's account of an amendment, not independently confirmed protocol information in this edition.","Stock scope and the update relayed by a speaker name IZABRIGHT-Lung01 but list NCT05983432 rather than this report's NCT07100080. Their development and dose statements require that qualification.","Some speakers' identities or clinical roles are not established in the sources used in this report; each statement is attributed only as far as its source shows.","The safety accounts concern different populations and studies, with differing ILD or pneumonitis descriptions. They do not support a pooled safety estimate or a general conclusion that pulmonary risk is absent.","Drug-related regulatory coverage was incomplete, and no exact iza-bren label was identified. Regulatory-interest commentary does not establish approval or a labeled use.","Site-opening plans, the approximately 2028 readout expectation and other forward-looking statements retain their original timing and uncertainty; subsequent events are not established here."]},"sources":{"cited_sources":{"by_channel":{"bluesky_thread":0,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":1,"regulatory":0,"x_thread":13,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":13,"methods":1},"count":14,"evidence_window":{"end":"2026-10-26","start":"2025-09-09"},"retrieval_snapshot":"2026-10-29T07:45:52.297844Z","timeline":[{"count":1,"week":"2025-W37"},{"count":2,"week":"2025-W42"},{"count":1,"week":"2026-W04"},{"count":2,"week":"2026-W34"},{"count":2,"week":"2026-W38"},{"count":5,"week":"2026-W44"}],"undated_sources":1},"quote_policies":[{"id":"clinicaltrials:NCT07100080:methods","quote_policy":"short_quote_link_out"},{"id":"clinicaltrials:NCT07100080:context","quote_policy":"short_quote_link_out"},{"id":"openfda:4c89cedc-e48b-445c-ad05-54dbe60e4fb0:20260721","quote_policy":"short_quote_link_out"},{"id":"openfda:508496cb-3441-46b3-a4fe-e0d440e6adc6:20260624","quote_policy":"short_quote_link_out"},{"id":"mcp:bluesky_thread:plc-pmmp7irwts7faw56jdxk3idc-3mvcrugxw4c52","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1965344286897004855:282c637d-30be-4c38-928a-01d9d0305092","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1971516630628028661:4f585b5f-ce01-457b-b047-58c7191995dc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979230598775607607:f6f77f1c-8c09-4db6-a4d8-f716e9a6ae8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979930902919594002:3d88f6c5-cd5a-4303-ab13-d74c518e1d8f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1979935107331817823:61f6964e-c84d-4b88-ae06-e4ddeece0799","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:1990797753308623318:5dbf7c24-1566-4714-b1ca-88aa1f298b72","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2014326204950515871:3e289f66-6181-4f8d-9109-e153ae7c78d5","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2089879779205882297:0f34234a-d557-424a-9db0-6de991802f81","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090144329620664467:85ade868-5693-4abf-b645-23cb468be1de","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2090154013601771552:9612f97e-caa8-4e80-bdfd-9d4e3900abfe","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099068062422945967:c94185b2-883c-4ae0-8b82-77a97889d246","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099342223628554499:0c4bc177-1353-4562-b5d8-ada43cf77934","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2099457633032008183:db7ba759-9273-4c5f-be44-78927ef25b6f","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2101004630117282022:d46f99b8-4735-4f7d-aeaf-20e43c1e20a8","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2113454214810591712:5bfa86ac-e739-4084-ac59-c06d30b1ab8c","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114608171100913921:ada57ae9-3e77-4ae4-9a98-fbdacf949f45","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114634069216526589:d1ed4344-6fae-4ec8-a406-005609092106","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635060494373050:2556caac-a932-4e12-a584-311c6d2603e1","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114635699425329372:7b79cb88-39d3-4e57-a7b1-3f3c60b493fc","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114643141995229588:6986eece-4fc3-4cee-9d16-e36cdd15c924","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114701269344354776:f93d021e-e17d-407b-b3bc-f5d22bb9b4e2","quote_policy":"short_quote_link_out"},{"id":"mcp:x_thread:2114742204459880760:ac897eb8-6329-4784-ac43-c304ad896dbc","quote_policy":"short_quote_link_out"}],"screened_sources":{"by_channel":{"bluesky_thread":1,"linkedin_post":0,"other":0,"podcast":0,"publication":0,"registry":0,"regulatory":0,"x_thread":22,"x_video":0,"youtube":0},"by_evidence_role":{"commentary":23},"count":23,"evidence_window":{"end":"2026-10-26","start":"2025-09-09"},"retrieval_snapshot":"2026-10-29T07:45:52.403045Z","timeline":[{"count":1,"week":"2025-W37"},{"count":1,"week":"2025-W39"},{"count":3,"week":"2025-W42"},{"count":1,"week":"2025-W47"},{"count":1,"week":"2026-W04"},{"count":3,"week":"2026-W34"},{"count":2,"week":"2026-W37"},{"count":3,"week":"2026-W38"},{"count":1,"week":"2026-W43"},{"count":7,"week":"2026-W44"}],"undated_sources":0}},"taxonomy":{"biomarkers":{"reason":"No structured, checked-in biomarker mapping for this trial.","status":"unmapped"},"conferences":{"reason":"No conferences in source metadata.","status":"none"},"drugs":[{"reason":"Unmapped registry intervention: iza-bren","status":"unmapped"},{"brand_names":["Paraplatin"],"label":"carboplatin","slug":"carboplatin"},{"brand_names":["Platinol"],"label":"cisplatin","slug":"cisplatin"},{"brand_names":["Alimta"],"label":"pemetrexed","slug":"pemetrexed"}],"indications":[{"brand_names":{"reason":"Indication, not a drug.","status":"not_applicable"},"label":"Non-small cell lung cancer","slug":"non-small-cell-lung-cancer"}],"line_of_therapy":{"reason":"No structured, checked-in line-of-therapy mapping for this trial.","status":"unmapped"},"therapeutic_area":["oncology"]},"trial":{"acronym":"IZABRIGHT-Lung01","aliases":["IZABRIGHT-Lung01","Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy"],"brief_title":"Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)","collaborators":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"conditions":["Non-Small Cell Lung Cancer"],"enrollment":{"count":500,"type":"ESTIMATED"},"interventions":[{"name":"Iza-bren","synonyms":["BMS-986507","BL-B01D1","Izalontamab brengitecan"],"type":"DRUG"},{"name":"Carboplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Cisplatin","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"},{"name":"Pemetrexed","synonyms":{"reason":"Not present in the acquired registry snapshot.","status":"unavailable"},"type":"DRUG"}],"nct_id":"NCT07100080","official_title":"IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy in Patients With EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy","overall_status":"RECRUITING","phase":["PHASE2","PHASE3"],"primary_completion_date":{"date":"2028-12-15","type":"ESTIMATED"},"primary_endpoints":[{"description":"Phase 2","measure":"Recommended Phase 3 Dose (RP3D) of BMS-986507","timeFrame":"Approximately 3 months after the first dose"},{"description":"Phase 3","measure":"Progression-Free Survival (PFS) Assessed by Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST v1.1) per blinded independent central review (BICR)","timeFrame":"Up to 3 years"}],"registered_date":{"date":"2025-08-03","type":"ACTUAL"},"registry_last_updated":"2026-10-09","registry_url":"https://clinicaltrials.gov/study/NCT07100080","short_name":"IZABRIGHT-Lung01","short_name_basis":"canonical_name","sponsor":"Bristol-Myers Squibb","start_date":{"date":"2025-11-05","type":"ACTUAL"},"study_design":"interventional, randomized, parallel, phase2, phase3","study_ids":[{"id":"CA244-0010","type":"sponsor_study_id"},{"domain":"2025-521908-22","id":"EU CTR","type":"other"},{"domain":"U1111-1321-3429","id":"WHO","type":"other"},{"domain":"Bristol-Myers Squibb Protocol ID","id":"CA2440010","type":"other"}],"study_type":"INTERVENTIONAL"}}}